No Shock for Cardiome

Cardiome (Nasdaq: CRME  ) is sitting pretty as the FDA took another step yesterday toward imminent approval of its lead drug, Vernakalant.

Now given the ugly-sounding brand name KYNAPID, Vernakalant was in testing as a treatment for acute atrial fibrillation (essentially irregular heart rhythm). Following two successful phase 3 trials, Cardiome and partner Astellas filed a marketing application with the FDA a year ago.

As the FDA made clear from its briefing documents released Monday, Vernakalant will almost certainly be approved by the agency by its Jan. 19 PDUFA target date (or, at worst, given a short approvable letter concerning labeling changes).

This likely course of FDA action was further reinforced by an advisory committee, which voted 6-2 yesterday in favor of recommending approval for Vernakalant. Like all advisory hearings, this vote is nonbinding.

Now that Vernakalant's regulatory fate has likely been determined, the torch is largely passed onto Astellas, which will be responsible for all marketing of the drug in the U.S. Unlike drugmakers such as Neurocrine Biosciences (Nasdaq: NBIX  ) , Encysive Pharmaceuticals (Nasdaq: ENCY  ) , or CV Therapeutics (Nasdaq: CVTX  ) , Cardiome won't be saddled with an expensive sales force without revenue coming in, and it can sit back while the royalties start to accrue. Cardiome also still owns rights to Vernakalant outside North America.

But even more important than the outcome of the intravenous version of the drug are the coming study results for the oral version of Vernakalant. The market for oral Vernakalant is much larger than the intravenous version: It is being tested as a treatment for chronic atrial fibrillation. Interim phase 2 results from oral Vernakalant are expected in March with final results coming in "mid-2008." Expect the wild times to continue with Cardiome until then.


Read/Post Comments (0) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 552155, ~/Articles/ArticleHandler.aspx, 7/25/2014 8:10:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement